Kymera Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kymera Therapeutics generated cash of -$102,826,000, which is more than the previous year. Cash used in financing activities reached the amount of $4,192,000 last year. Net change in cash is therefore $41,252,000.
Cash Flow
| 2018 | -17.86M | -1.35M | 52.93M |
|---|---|---|---|
| 2019 | 17.90M | -16.48M | 34.91M |
| 2020 | 88.13M | -422.58M | 289.26M |
| 2021 | -128.94M | -99.83M | 250.28M |
| 2022 | -153.08M | 20.51M | 152.99M |
| 2023 | -102.82M | 139.88M | 4.19M |
KYMR Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 74.52M | 54.09M | 32.59M | 77.78M | 41.45M | 7.74M |
Operating activities | ||||||
Net income | -146.96M | -154.80M | -100.21M | -45.59M | -41.24M | -21.46M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 3.56M | 2.97M | 2.39M | 1.76M | 825K | 205K |
Stock-based compensation expense | 43.11M | 35.48M | 24.97M | 5.19M | 1.19M | 0 |
| Deferred income tax benefit | 43.11M | 35.48M | 24.97M | 5.19M | 1.19M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -15M | -2.40M | 577K | -577K | 148K | 0 |
Inventories | 23.37M | 2.40M | 8.70M | 6.87M | -148K | 0 |
Accounts payable | 2.03M | 253K | 54K | 990K | 904K | 824K |
Cash generated by operating activities | -102.82M | -153.08M | -128.94M | 88.13M | 17.90M | -17.86M |
Investing activities | ||||||
Purchases Of Investments | -189.15M | -445.97M | -456.40M | -529.38M | -15.95M | 0 |
Investments In Property Plant And Equipment | -34.48M | -2.83M | -1.59M | -9.09M | -532K | -1.35M |
Acquisitions Net | 0 | -20.51M | 5.80M | 413.49M | 0 | 0 |
Cash generated by investing activities | 139.88M | 20.51M | -99.83M | -422.58M | -16.48M | -1.35M |
Financing activities | ||||||
Common Stock Issued | 4.26M | 149.82M | 243.10M | 196.67M | 35.28M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -76K | -1.13M | -849K | -554K | -371K | -295K |
Cash used in financing activities | 4.19M | 152.99M | 250.28M | 289.26M | 34.91M | 52.93M |
Net Change In Cash | 41.25M | 20.43M | 21.49M | -45.19M | 36.33M | 33.71M |
Cash at end of period | 115.77M | 74.52M | 54.09M | 32.59M | 77.78M | 41.45M |
| Data source | Data source | Data source | Data source |